RecruitingPhase 2NCT05160506

Corticosteroids to Treat Pancreatitis

Corticosteroids to Reduce Inflammation in Severe Pancreatitis: A Randomized, Controlled Study

Sponsor

Beth Israel Deaconess Medical Center

Enrollment

86 participants

Start Date

Mar 6, 2022

Study Type

INTERVENTIONAL

Conditions

Pancreatitis Hydrocortisone Pancreatitis, Acute Corticosteroid

Summary

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether corticosteroids (anti-inflammatory medications) can improve outcomes for patients in the ICU with severe acute pancreatitis — a serious inflammation of the pancreas. You may be eligible if: - You are 18 or older - You have a diagnosis of acute pancreatitis confirmed by elevated lipase levels (3x normal) - You have been admitted or are being admitted to the intensive care unit (ICU) - Your disease severity score (SOFA) is 3 or higher You may NOT be eligible if: - You have known autoimmune pancreatitis - You are already taking corticosteroids above a low dose (more than 5 mg prednisone/day) - You have a medical reason you cannot take corticosteroids - You are a prisoner - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.